Need help choosing the right code?
Ask CasePilot about procedures, modifiers, bundling, and coding guidance.
Try CasePilot© Copyright 2026 American Medical Association. All rights reserved.
The CPT® Code 80330 refers to a laboratory test specifically designed to measure the presence of non-opioid analgesics in biological samples such as urine, serum, or plasma. Non-opioid analgesics are a category of medications that are utilized to alleviate pain without the use of opioids. This group includes various substances such as salicylates, which encompass aspirin, acetaminophen, and non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and naproxen sodium. Additionally, selective cyclooxygenase-2 (COX-2) inhibitors, such as Celebrex, are also classified under this category. These medications are commonly prescribed for the management of both acute and chronic pain, ranging from mild to moderate intensity, and they may be used in conjunction with opioids or other analgesic compounds to address moderate to severe pain. Beyond their primary function of pain relief, many of these analgesics possess anti-inflammatory and anti-pyretic properties, making them versatile in treating various conditions. The testing methods for these substances vary; for instance, salicylates and acetaminophen are typically measured using spectrophotometry, while ibuprofen and naproxen sodium are analyzed through high-performance liquid chromatography. It is important to note that CPT® Code 80330 is specifically designated for the testing of three to five non-opioid analgesic compounds, whereas other codes, such as 80329 and 80331, are used for testing fewer or more than five compounds, respectively.
© Copyright 2026 Coding Ahead. All rights reserved.
Assessment of Pain Management: The procedure is indicated for patients who are undergoing treatment with non-opioid analgesics to evaluate the effectiveness of pain management strategies.
Monitoring Drug Levels: This test is performed to monitor the levels of non-opioid analgesics in patients who may be at risk of toxicity or adverse effects due to high concentrations of these medications.
Compliance Verification: The test can be used to verify patient compliance with prescribed non-opioid analgesic regimens, ensuring that patients are taking their medications as directed.
Evaluation of Side Effects: It is indicated for patients experiencing side effects that may be related to the use of non-opioid analgesics, allowing healthcare providers to make informed decisions regarding treatment adjustments.
Step 1: The first step in the procedure involves the collection of biological samples, which may include urine, serum, or plasma, depending on the specific non-opioid analgesics being tested. Proper collection techniques must be followed to ensure the integrity of the samples.
Step 2: Once the samples are collected, they are prepared for analysis. This may involve processes such as centrifugation for serum or plasma samples to separate the liquid portion from the cellular components.
Step 3: The prepared samples are then subjected to specific analytical techniques based on the type of non-opioid analgesics being tested. For salicylates and acetaminophen, spectrophotometry is utilized, which measures the absorbance of light by the compounds in the sample. For ibuprofen and naproxen sodium, high-performance liquid chromatography (HPLC) is employed, allowing for the separation and quantification of these drugs in the sample.
Step 4: After the analysis is complete, the results are compiled and interpreted by laboratory professionals. The findings will indicate the presence and concentration of the non-opioid analgesics tested, providing valuable information for the healthcare provider.
Post-procedure care involves the proper handling and storage of the test results, which should be communicated to the healthcare provider for further evaluation. Patients may not require any specific post-procedure care related to the test itself, but it is essential for healthcare providers to review the results in the context of the patient's overall treatment plan. Follow-up appointments may be necessary to discuss the findings and make any necessary adjustments to the patient's analgesic regimen based on the test results. Additionally, if any adverse effects or concerns arise from the use of non-opioid analgesics, further evaluation and management may be warranted.
| Short Descr | ANALGESICS NON-OPIOID 3-5 | Medium Descr | DRUG SCREEN ANALGESICS NON-OPIOID 3-5 | Long Descr | Analgesics, non-opioid; 3-5 | Status Code | Not Valid for Medicare Purposes | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | APC Status Indicator | Code Not Recognized by OPPS when submitted on Outpatient Hospital Part B Bill Type (12x/13x) | Type of Service (TOS) | 5 - Diagnostic Laboratory | Berenson-Eggers TOS (BETOS) | T2D - Other tests - other | MUE | 1 |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2015-01-01 | Added | Added |
Get instant expert-level medical coding assistance.